TY  - GEN
AU  - van Santen, Daniela K
AU  - Sacks-Davis, Rachel
AU  - Stewart, Ashleigh
AU  - Boyd, Anders
AU  - Young, Jim
AU  - van der Valk, Marc
AU  - Smit, Colette
AU  - Rauch, Andri
AU  - Braun, Dominique L
AU  - Jarrin Vera, Inmaculada
AU  - Berenguer, Juan
AU  - Lazarus, Jeffrey V
AU  - Lacombe, Karine
AU  - Requena, Maria-Bernarda
AU  - Wittkop, Linda
AU  - Leleux, Olivier
AU  - Salmon, Dominique
AU  - Bonnet, Fabrice
AU  - Matthews, Gail
AU  - Doyle, Joseph S
AU  - Spelman, Tim
AU  - Klein, Marina B
AU  - Prins, Maria
AU  - Asselin, Jason
AU  - Stoové, Mark A
AU  - Hellard, Margaret
AU  - InCHEHC study group
PY  - 2022
DO  - 10.1016/j.eclinm.2022.101810
UR  - http://hdl.handle.net/20.500.12105/15826
AB  - Background: Broad direct-acting antiviral (DAA) access may reduce hepatitis C virus (HCV) incidence through a "treatment as prevention" (TasP) effect. We assessed changes in primary HCV incidence following DAA access among people living with HIV...
LA  - eng
PB  - Elsevier
KW  - HIV
KW  - Hepatitis C virus
KW  - Elimination
KW  - Direct-acting antivirals
KW  - Trends
KW  - Incidence
TI  - Treatment as prevention effect of direct-acting antivirals on primary hepatitis C virus incidence: Findings from a multinational cohort between 2010 and 2019
TY  - research article
ER  -